Release Date: November 2018
CMLE Credit Only
Elizabeth Sheppard, HT(ASCP) MBA
Senior Director Market Access, Roche Tissue Diagnostics, Tucson, AZ
Immunotherapy is an area of great interest today because these drugs have demonstrated higher progression-free survival and overall response rates compared to chemotherapy in patients with very advanced cancers. The applications for immunotherapy are very rapidly demonstrating usefulness across multiple tumor types.
Currently there are several companion and complementary PD-L1 tests that have been approved by the FDA for use in CLIA-certified laboratories, based on which immunotherapy is initiated for specific tumor types. This webcast is designed to educate participants about immunotherapy, the role of PD-L1, and PD-L1 detection methods.
After attending this session, participants will be able to:
- Know what PD-L1 is and the rationale for PD-L1 testing.
- Know which cancers are being evaluated for PD-L1 therapy.
- Know how PD-L1 is detected.
Who should attend? Practicing Pathologists, Residents, Pathologists’ Assistants, Laboratory Managers, Bench Supervisors, Cytotechnologists, Histotechnologists